Skip to content

Cardioprotective Effect of RIPC in Patients Undergoing TAVI

The CARE-TAVI Study: Cardioprotective Effect of Remote Ischemic Preconditioning in Patients Undergoing Transcatheter Aortic Valve Implantation

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02283398
Acronym
CARE-TAVI
Enrollment
0
Registered
2014-11-05
Start date
2014-11-30
Completion date
2016-04-30
Last updated
2015-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Effectivity of RIPC in Outcomes of TAVI Procedure

Brief summary

We aim to investigate whether RIPC (remote ischemic preconditioning) is effective in the TAVI setting to reduce post-procedural myocardial damage and improve patient outcome. Accordingly, we aim to investigate whether RIPC can be introduced as an integral part of the TAVI procedure, in order to reduce post-procedural myocardial damage and potentially improve patient outcome.

Detailed description

Transcatheter aortic valve implantation (TAVI) is associated to myocardial injury, defined as post-procedural cardiac troponin (cTn) elevation. Earlier experiences have shown that myocardial damage can be encountered in a percentage of patients that varies from 1.5% to 17%, depending on the access route (transfemoral and transapical, respectively). The degree of rise in cTn after TAVI emerged as an independent predictor of mortality. Remote ischaemic preconditioning (RIPC) consists of brief episodes of ischaemia applied to remote organs or tissues and has shown to result in a significant reduction in postoperative troponin levels in cardiac and non-cardiac surgery patients. Lately, growing evidence suggests that post-procedural troponin decreases due to RIPC application protocols protocols and is associated with improved outcome. The patients will be divided into two Groups. In Group 1, RIPS will be induced with three cycles of Inflation of a blood-pressure cuff on the left arm to 200 mmHg for 5 min., followed by 5 min. of reperfusion while the cuff is deflated. In controls (Group 2), the cuff will be placed around the left arm without being inflated.

Interventions

OTHERwithout RIPC

the cuff will be placed around the left arm without being inflated

PROCEDURERIPC

RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated

Sponsors

Institut für Pharmakologie und Präventive Medizin
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Indication for elective TAVI following Heart Team discussion * Stable hemodynamic conditions without circulatory support or catecholamines

Exclusion criteria

* Myocardial infarction at least 3 months before enrollment * Stroke/TIA at least 3 months before enrollment * Severe chronic kidney disease (defined as a baseline serum creatinine of \> 1.5 mg/dl or an estimated glomerular filtration rate (eGFR) of 60 ml/min/1.73 m2 ) * PCI at least 3 months before enrollment * Abnormal (\>99th percentile of laboratory cut-off) baseline values of biomarkers of myocardial ischemia (i.e. TnT, CK-MB) * Abnormal NSE values at baseline (local laboratory cut-off values)

Design outcomes

Primary

MeasureTime frameDescription
post-procedural myocardial injury, defined by the geometric mean (95% CI) of the area under the curve (AUC) for cTnT72 hours after interventionChange in cardiac troponine T (cTnT)

Secondary

MeasureTime frameDescription
Post-procedural myocardial injury72 hours after interventiondefined by the geometric mean (95% CI) of the area under the curve (AUC) for CK-MB
Post-procedural acute kidney injury72 hours after interventiondefined according to the VARC 2 criteria
Post-procedural brain injury72 hours after interventiondefined by the geometric mean (95% CI) of the area under the curve (AUC) for NSE
composite of major adverse cardiac and cerebrovascular eventsdischarge, at 30 days and at 1 yearincluding death, postoperative myocardial infarction and cerebrovascular accident or stroke

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026